BTTX - Better Therapeutics - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

BTTX is currently covered by 2 analysts

Better Therapeutics's activity chart (see below) currently has 2 price targets and 9 ratings on display. The stock rating distribution of BTTX is 100% BUY.

Stock Analyst Price Targets - Review

Highest price target for BTTX is $3, Lowest price target is $1.

Most recent stock forecast was given by KEAY NAKAE from CHARDAN CAPITAL on 10-Aug-2023. First documented stock forecast 24-Nov-2021.

Best performing analysts who are covering BTTX - Better Therapeutics:

Keay Nakae Thomas Flaten

Currently out of the existing stock ratings of BTTX, 7 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Keay Nakae (CHARDAN CAPITAL)

Buy

3 years 1 months 11 days ago
(10-Aug-2023)

0/2 (0%)

$10.32 (154.49%)

Please subscribe to see extended stock data

Thomas Flaten (LAKE STREET)

Buy

$2.85 (1900.00%)

3 years 1 months 11 days ago
(10-Aug-2023)

0/2 (0%)

$2.27 (310.96%)

Please subscribe to see extended stock data

Show more analysts

Load Price Targets and Ratings Chart

Please expand the browser size to see the chart

Which analyst most recently updated their price target on BTTX (Better Therapeutics)?

Keay Nakae

Which analyst has the current lower performing score on BTTX (Better Therapeutics) with a proven track record?

THOMAS FLATEN

Which analyst has the most public recommendations on BTTX (Better Therapeutics)?

Keay Nakae works at CHARDAN CAPITAL and has 2 price targets and 7 ratings on BTTX

Which analyst is the currently most bullish on BTTX (Better Therapeutics)?

Thomas Flaten with the highest potential upside of $2.85

Which analyst is the currently most reserved on BTTX (Better Therapeutics)?

Keay Nakae with the lowest potential downside of -$0